Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | XDH | P47989 | 1/20 | 0.51 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | THRA | P10827 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30285469 | 0.86 | MAOA (0.53) | KDRMAOAMAPTRAB9ATHRA | |
| SCHEMBL29336889 | 0.86 | MAOA (0.53) | KDRMAOAMAPTRAB9ATHRA | |
| SCHEMBL16741838 | 0.85 | AKR1C3 (0.59) | MAOANPC1MAPTRAB9ACTNNB1 | |
| SCHEMBL22169914 | 0.84 | MET (0.49) | L3MBTL1XDHCDK8METALK | |
| SCHEMBL30967902 | 0.83 | NPC1 (0.47) | MAOANPC1MAPTRAB9ATHRA | |
| SCHEMBL29237301 | 0.83 | NPC1 (0.47) | MAOANPC1MAPTRAB9ATHRA | |
| SCHEMBL18941171 | 0.82 | AR (0.61) | L3MBTL1MAOANPC1MAPTRAB9A | |
| SCHEMBL31176890 | 0.82 | L3MBTL1 (0.55) | KDRL3MBTL1CDK8METALK | |
| SCHEMBL31176896 | 0.82 | L3MBTL1 (0.55) | KDRL3MBTL1CDK8METALK | |
| SCHEMBL103794 | 0.81 | TUBB4A (0.58) | KDRCDK8MAOANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | CFTR, INMT, IDO1 | KDR 4872/4885L3MBTL1 3265/4885XDH 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.